Sorrento Therapeutics Inc
NASDAQ:SRNE
| Market Cap (Intraday) | 2.04B |
| Current PE | N/A |
| Forward PE | 6.41 |
| 2yr Forward PE | 3.39 |
| 10-Day MA | $8.03 |
| 50-Day MA | $10.83 |
| 200-Day MA | $9.10 |
Sorrento Therapeutics, Inc. Stock, NASDAQ:SRNE
4955 Directors Place, 4955 Directors Place, San Diego, California 92121
United States of America
Phone: +1.858.203.4100
Number of Employees: 502
Description
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.